Author:
Marques Rui Pedro,Duarte Gonçalo S.,Sterrantino Carmelo,Pais Helena Luna,Quintela António,Martins Ana Paula,Costa João
Reference40 articles.
1. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial;Andre;J. Clin. Oncol.,2009
2. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial;Assenat;Oncologist,2011
3. Overal l response rate in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab vs FOLFOX-bevacizumab for the first-line treatment of patients with metastatic colorectal cancer;Bendell;ASCO Gastrointestinal Cancers Symposium,2016
4. First-line chemotherapy for mCRC-a review and evidence-based algorithm;Cremolini;Nat. Rev. Clin. Oncol.,2015
5. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study;Cremolini;Lancet Oncol.,2015
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Camptothesome-based combination nanotherapeutic regimen for improved colorectal cancer immunochemotherapy;Biomaterials;2024-04
2. Age-related trends in the incidence of metastatic colorectal cancer from 2010 to 2019 in the USA;Future Oncology;2023-09-13
3. Identification of Moesin (MSN) as a Potential Therapeutic Target for Colorectal Cancer via the β-Catenin-RUNX2 Axis;International Journal of Molecular Sciences;2023-06-30
4. 2,3,5,4′-Tetrahydroxystilbene (TG1), a Novel Compound Derived from 2,3,5,4′-Tetrahydroxystilbene-2-O-β-D-glucoside (THSG), Inhibits Colorectal Cancer Progression by Inducing Ferroptosis, Apoptosis, and Autophagy;Biomedicines;2023-06-23
5. A Multi-Omics Overview of Colorectal Cancer to Address Mechanisms of Disease, Metastasis, Patient Disparities and Outcomes;Cancers;2023-05-26